01—Abstract
Summary
Summary of the 10-K filed February 26, 2024. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines (formerly BeiGene, ticker ONC on the filing's naming; the filing itself is BeiGene, Ltd., Nasdaq: BGNE) reported total 2023 revenue of $2.46 billiona, up 73.7% from $1.42 billion in 2022, while net loss narrowed 56% to $881.7 million from $2.0 billion.
Growth was driven by BRUKINSA, whose global sales rose 128.5% to $1.29 billionb, with U.S. sales up 142.6% to $945.6 million, and by tislelizumab (TEVIMBRA) in China, up 26.9% to $536.6 million. Collaboration revenue of $268.9 million was boosted by the one-time recognition of deferred revenue after the Novartis tislelizumab and ociperlimab agreements were terminated in 2023. Profitability remains distant.
Loss from operations was $1.21 billionc, improved from $1.79 billion, as product gross margin expanded to roughly 83% and operating expenses grew 12.6% to $3.29 billion. Adjusted operating loss narrowed to $752 million. Net loss was also flattered by a non-cash $362.9 million gain from the BMS settlement, which returned 23.3 million shares.
The company held $3.2 billiond of cash and equivalents at year-end, against $886 million of debt, most of it short-term, and reported an accumulated deficit of $8.0 billion. Management states current cash should fund operations for at least 12 months. Key investor watch items include continued BRUKINSA launch momentum in the U.S. and Europe, the pace of Chinese NRDL price reductions on tislelizumab and other products, the cash burn from ongoing R&D (including sonrotoclax Phase 3 programs) and capital spending on the Hopewell, New Jersey facility, and risks tied to PRC regulation, HFCAA compliance, and the Pharmacyclics patent suit against BRUKINSA.
02—Key points
Key Highlights
- Total revenue rose 73.7% to $2.46B in 2023; product revenue reached $2.19B (+74.5%).
- BRUKINSA global sales grew 128.5% to $1.29B, with U.S. sales up 142.6% to $945.6M after the CLL/SLL approval and launch.
- Net loss narrowed 56% to $881.7M from $2.0B; loss from operations improved to $1.21B from $1.79B.
- Product gross margin expanded to 82.7% from 77.2%, driven by volume and regional mix.
- The net loss benefited from a non-cash $362.9M gain on the August 2023 BMS settlement, which returned 23.3M shares.
- Year-end cash and equivalents were $3.2B against $886M of total debt; management expects existing cash to fund operations for at least 12 months.
- Accumulated deficit reached $8.0B, and the company still expects to incur net losses, with R&D spend of $1.78B and SG&A of $1.50B.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2023, BeOne Medicines Ltd. lost $0.36.
- Revenue$2.46B100.0%
- Cost of revenue−$379.9M15.5%
- Gross profit$2.08B84.5%
- Operating costs−$3.29B133.7%
- Operating income−$1.21B49.1%
- Interest, other & tax$326.0M13.3%
- Net income−$881.7M35.9%
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 26, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $2.46B$1.42B | +73.7% |
| Gross Profit | $2.08B$1.13B | +84.1% |
| R&D Expenses | $1.78B$1.64B | +8.4% |
| SG&A Expenses | $1.51B$1.28B | +17.9% |
| Operating Expenses | $3.29B$2.92B | +12.6% |
| Operating Income | -$1.21B-$1.79B | +32.5% |
| Interest Expense | $20.80M$21.70M | −4.1% |
| Net Income | -$881.71M-$2.00B | +56.0% |
| EPS (Basic) | $-0.65$-1.49 | +56.4% |
| EPS (Diluted) | $-0.65$-1.49 | +56.4% |
| Shares Outstanding (Basic) | 1.36B1.34B | +1.2% |
| Shares Outstanding (Diluted) | 1.36B1.34B | +1.2% |
05—Questions
Frequently Asked Questions
How much of the revenue growth was organic product sales versus one-time items?
Product revenue of $2.19B accounts for most of the $1.04B increase. Collaboration revenue of $269M rose $108M, but it was largely a one-time recognition of remaining deferred revenue after the Novartis agreements were terminated in 2023, and management expects collaboration revenue to decline in 2024.
When does BeiGene expect to reach profitability?
The filing does not provide a profitability timeline. Management says it expects losses to decline as product sales growth outpaces expense growth, but it also says it may never become profitable.
What drove the lower net loss in 2023?
The improvement came mainly from a $1.04B increase in revenue and a $582M reduction in operating loss. Other income of $308M, which included the $363M non-cash BMS settlement gain, also contributed. Operating expenses rose 12.6%, partly offsetting these gains.
What are the main risks around China revenue and regulation?
China generated about 45% of 2023 revenue. Risks include NRDL price cuts and volume-based procurement that reduce prices, PRC regulation of overseas listings and data (HGR, CSRC filing, and cybersecurity review), and possible limits on dividends from PRC subsidiaries. Restricted PRC net assets totaled $4.1B.
Is the company exposed to significant debt maturities or liquidity risk?
Total debt was $886M, of which $688M is due within 12 months, mostly short-term bank loans in China. The company says it expects to refinance these on a consistent basis, and it was in compliance with all covenants at year-end.
06—Continue